Trial Profile
Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Registrational
- Acronyms ROSiA
- Sponsors Roche
- 01 Sep 2019 Results exploring the effect of discordant surgically and radiologically assessed postoperative residual disease on prognosis published in the Journal of Surgical Oncology.
- 12 Sep 2017 Results (n=154) of gene mutational analysis assessing prevalence of gene alterations, tumour mutational burden (TMB) and potential prognostic effects presented at the 42nd European Society for Medical Oncology Congress
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology